Gosset Sangamo Therapeutics General Information
Sangamo is a pioneer in genomic medicine using proprietary zinc finger technology platforms. Its lead wholly owned programs target serious neurological and rare genetic diseases. The company has advanced its neurology pipeline toward the clinic and secured major licensing deals with Genentech and Astellas for novel capsid delivery technologies. The Fabry disease program is on an accelerated regulatory path after positive Phase I/II data; a pivotal BLA submission is anticipated in the second half of 2025. An IND was cleared for ST‑503 in iSFN pain with first patient dosing expected mid‑2025. Nonclinical proof-of-concept was demonstrated in prion disease models.[6][8]
Contact Information
United States
Drug Pipeline
Key Partnerships
Genentech/Roche – global epigenetic regulation & capsid delivery license agreement for neurodegenerative diseases[6], Astellas – capsid license agreement targeting up to five neurological indications[6], Previous or ongoing collaborations have included Pfizer, Biogen, Kite/Gilead, Lilly, Alexion, Takeda.[5][10]
Sangamo Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Feb 4, 2026 | $25.0M | Completed | Phase 3 |